Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
December 10, 2022 14:20 ET
|
Affimed N.V.
AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patientsPatients had...
Affimed to Host Investor Event Highlighting AFM13 Clinical Development at 2022 ASH Annual Meeting
December 01, 2022 16:05 ET
|
Affimed N.V.
Review of clinical data and development plans for AFM13 in hematologic malignanciesLive event and webcast on Saturday, December 10 at 4:00 p.m. CST HEIDELBERG, Germany,, Dec. 01, 2022 (GLOBE...
Affimed Reports Third Quarter 2022 Financial Results and Highlights Recent Clinical and Corporate Progress
November 15, 2022 06:30 ET
|
Affimed N.V.
AFM13: Secured access to commercially viable natural killer (NK) cell product to accelerate clinical development of AFM13 and address the high unmet need of CD30-positive lymphoma patients through a...
Affimed Provides Data Update from Two Phase 1/2a Trials with its Innate Cell Engager AFM24 in Solid Tumor Patients at the 37th SITC Annual Meeting
November 07, 2022 08:05 ET
|
Affimed N.V.
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a...
Affimed to Report Third Quarter 2022 Financial Results & Corporate Update on November 15, 2022
November 04, 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
November 03, 2022 09:15 ET
|
Affimed N.V.
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patientsAffimed’s AFM13 in combination with cord blood-derived NK cells demonstrated...
Affimed Announces Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells and Preclinical AFM28 Data at ASH 2022 Annual Meeting
November 03, 2022 09:05 ET
|
Affimed N.V.
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an...
Affimed to Present at the 2022 Jefferies London Healthcare Conference
November 01, 2022 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Two Clinical Update Presentations on its Novel Bispecific Innate Cell Engager AFM24 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 05, 2022 08:05 ET
|
Affimed N.V.
A poster evaluating comprehensive correlative science findings from the AFM24 monotherapy phase 1 study (AFM24-101) will be presentedIn a second poster presentation, initial phase 1 dose escalation...
Affimed To Provide a Clinical Update on AFM24 Monotherapy Dose-escalation at European Society for Medical Oncology (ESMO) Congress 2022
September 04, 2022 18:05 ET
|
Affimed N.V.
Selected recommended phase 2 dose (RP2D) of 480 mg with ongoing enrollment in disease-specific cohorts; maximum tolerated dose (MTD) not reachedStable disease was observed in 10 of 27 evaluable...